Dersimelagon
Small moleculeexperimental
Clinical trial activity
13 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
8
Phase 2
5
Phase 3
3
Phase 4
0
Earliest trial started Jul 1, 2016 (NCT02834442)
Timeline
Indications
Mechanism of action
- Melanocortin receptor 1AGONIST
MC1R agonist
Chemistry & pharmacology
Loading structure…
SMILES
COC[C@H]1CN(C(=O)[C@]2(F)CN(C3CCCC3)C[C@H]2c2ccc(OC)cc2)C[C@@H]1c1ccc(C(F)(F)F)cc1N1CCC(C(=O)O)CC1- Mol. weight
- 675.76 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4802160 ↗
Also known as
- mt-7117
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06994286 | Phase 1 | Jun 24, 2025 | Mitsubishi Tanabe |
| NCT06144840 | Phase 3 | Dec 11, 2023 | Mitsubishi Tanabe |
| NCT05241535 | Phase 1 | Jan 12, 2022 | Mitsubishi Tanabe |
| NCT05005975 | Phase 3 | Aug 10, 2021 | Mitsubishi Tanabe |
| NCT04793295 | Phase 1 | Mar 23, 2021 | Mitsubishi Tanabe |
| NCT04656795 | Phase 1 | Dec 2, 2020 | Mitsubishi Tanabe |
| NCT04440592 | Phase 2 | Jul 31, 2020 | Mitsubishi Tanabe |
| NCT04402489 | Phase 3 | May 31, 2020 | Mitsubishi Tanabe |
| NCT04116476 | Phase 1 | Aug 1, 2019 | Mitsubishi Tanabe |
| NCT03688022 | Phase 1 | Oct 31, 2018 | Mitsubishi Tanabe |
| NCT03520036 | Phase 2 | Jul 5, 2018 | Mitsubishi Tanabe |
| NCT03503266 | Phase 1 | Mar 23, 2018 | Mitsubishi Tanabe |
| NCT02834442 | Phase 1 | Jul 1, 2016 | Mitsubishi Tanabe |
Showing 13 of 13 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Mitsubishi Tanabe | For profit | 13 | 13 | 3 | 2016 |
1 organizations
Page 1 / 1